NCT05618119

Brief Summary

P-gp is one of the main efflux transporters at the blood-brain barrier and is responsible for the transport of a variety of neurotoxic substances, including pharmaceuticals. Multiple studies report gender differences in therapeutic outcomes, toxicity and side effects for many drug agents. P-gp plays an important role in the bio-availability, drug distribution, metabolism and elimination of pharmaceuticals labelled as P-gp substrates (e.g. the majority of antidepressants and antipsychotics). A difference in P-gp function was already reported in hepatic P-gp expression. The aim of the current study is to evaluate the influence of gender on cerebral P-gp function. Outcomes of this study can be of great importance in gender-based prescription of P-gp substrate pharmaceuticals.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
10

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Jan 2023

Typical duration for not_applicable

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 8, 2022

Completed
8 days until next milestone

First Posted

Study publicly available on registry

November 16, 2022

Completed
2 months until next milestone

Study Start

First participant enrolled

January 1, 2023

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2024

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2025

Completed
Last Updated

November 16, 2022

Status Verified

November 1, 2022

Enrollment Period

1 year

First QC Date

November 8, 2022

Last Update Submit

November 8, 2022

Conditions

Keywords

P-glycoproteinMC225[18F]MC225PET

Outcome Measures

Primary Outcomes (1)

  • PET kinetic modeling outcome parameters [18F]MC225

    volume of distribution, K1, k2

    60 minutes after administration [18F]MC225

Secondary Outcomes (1)

  • PET kinetic modeling outcome parameters [15O]H2O

    10 minutes after administration of [15O]H2O

Study Arms (2)

Male

ACTIVE COMPARATOR

5 male participants will undergo a \[18F\]MC225 PET scan

Drug: [18F]MC225

Female

ACTIVE COMPARATOR

5 female participants will undergo a \[18F\]MC225 PET scan

Drug: [18F]MC225

Interventions

\[18F\]MC225 PET scan

FemaleMale

Eligibility Criteria

Age50 Years - 80 Years
Sexall(Gender-based eligibility)
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Healthy volunteers

You may not qualify if:

  • Use of medication with a known effect on the BBB P-glycoprotein transporter
  • Any history of neurological or psychiatric conditions affecting the BBB P-glycoprotein function

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (1)

  • Salvi de Souza G, Mossel P, Somsen JF, Providencia L, Bartels AL, Willemsen ATM, Dierckx RAJO, Furini CRG, Lammertsma AA, Tsoumpas C, Luurtsema G. Evaluating image-derived input functions for cerebral [18F]MC225 PET studies. Front Nucl Med. 2025 Jun 5;5:1597902. doi: 10.3389/fnume.2025.1597902. eCollection 2025.

MeSH Terms

Conditions

Coitus

Interventions

MC225 compound

Condition Hierarchy (Ancestors)

Sexual BehaviorBehavior

Central Study Contacts

Pascalle Mossel, Msc

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
BASIC SCIENCE
Intervention Model
PARALLEL
Model Details: Two groups of healthy volunteers (5 male, 5 female)
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Prof.

Study Record Dates

First Submitted

November 8, 2022

First Posted

November 16, 2022

Study Start

January 1, 2023

Primary Completion

January 1, 2024

Study Completion

January 1, 2025

Last Updated

November 16, 2022

Record last verified: 2022-11

Data Sharing

IPD Sharing
Will not share